Sökning: WFRF:(Pike I) > Menopausal hormone ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 09285naa a2202113 4500 | |
001 | oai:lup.lub.lu.se:0f8db601-1edb-451d-a8af-01983fa6f808 | |
003 | SwePub | |
008 | 160401s2015 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:131237033 | |
024 | 7 | a https://lup.lub.lu.se/record/74320122 URI |
024 | 7 | a https://doi.org/10.1016/S0140-6736(14)61687-12 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1312370332 URI |
040 | a (SwePub)lud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Gapstur, S. M.4 aut |
245 | 1 0 | a Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies |
264 | 1 | c 2015 |
338 | a electronic2 rdacarrier | |
520 | a Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk. Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use. Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even with <5 years of use (RR 1.43, 95% CI 1.31-1.56; p<0.0001). Combining current-or-recent use (any duration, but stopped <5 years before diagnosis) resulted in an RR of 1.37 (95% CI 1.29-1.46; p<0.0001); this risk was similar in European and American prospective studies and for oestrogen-only and oestrogen-progestagen preparations, but differed across the four main tumour types (heterogeneity p<0.0001), being definitely increased only for the two most common types, serous (RR 1.53, 95% CI 1.40-1.66; p<0.0001) and endometrioid (1.42, 1.20-1.67; p<0.0001). Risk declined the longer ago use had ceased, although about 10 years after stopping long-duration hormone therapy use there was still an excess of serous or endometrioid tumours (RR 1.25, 95% CI 1.07-1.46, p=0.005). Interpretation The increased risk may well be largely or wholly causal; if it is, women who use hormone therapy for 5 years from around age 50 years have about one extra ovarian cancer per 1000 users and, if its prognosis is typical, about one extra ovarian cancer death per 1700 users. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Patel, A. V.4 aut |
700 | 1 | a Banks, E.4 aut |
700 | 1 | a Dal Maso, L.4 aut |
700 | 1 | a Talamini, R.4 aut |
700 | 1 | a Chetrit, A.4 aut |
700 | 1 | a Hirsh-Yechezkel, G.4 aut |
700 | 1 | a Lubin, F.4 aut |
700 | 1 | a Sadetzki, S.4 aut |
700 | 1 | a Beral, V.4 aut |
700 | 1 | a Bull, D.4 aut |
700 | 1 | a Cairns, B.4 aut |
700 | 1 | a Crossley, B.4 aut |
700 | 1 | a Gaitskell, K.4 aut |
700 | 1 | a Goodill, A.4 aut |
700 | 1 | a Green, J.4 aut |
700 | 1 | a Hermon, C.4 aut |
700 | 1 | a Key, T.4 aut |
700 | 1 | a Moser, K.4 aut |
700 | 1 | a Reeves, G.4 aut |
700 | 1 | a Sitas, F.4 aut |
700 | 1 | a Collins, R.4 aut |
700 | 1 | a Peto, R.4 aut |
700 | 1 | a Gonzalez, C. A.4 aut |
700 | 1 | a Lee, N.4 aut |
700 | 1 | a Marchbanks, P.4 aut |
700 | 1 | a Ory, H. W.4 aut |
700 | 1 | a Peterson, H. B.4 aut |
700 | 1 | a Wingo, P. A.4 aut |
700 | 1 | a Martin, N.4 aut |
700 | 1 | a Silpisornkosol, S.4 aut |
700 | 1 | a Theetranont, C.4 aut |
700 | 1 | a Boosiri, B.4 aut |
700 | 1 | a Chutivongse, S.4 aut |
700 | 1 | a Jimakorn, P.4 aut |
700 | 1 | a Virutamasen, P.4 aut |
700 | 1 | a Wongsrichanalai, C.4 aut |
700 | 1 | a Goodman, M. T.4 aut |
700 | 1 | a Lidegaard, O.4 aut |
700 | 1 | a Kjaer, S. K.4 aut |
700 | 1 | a Morch, L. S.4 aut |
700 | 1 | a Kjaer, S. K.4 aut |
700 | 1 | a Tjonneland, A.4 aut |
700 | 1 | a Byers, T.4 aut |
700 | 1 | a Rohan, T.4 aut |
700 | 1 | a Mosgaard, B.4 aut |
700 | 1 | a Vessey, M.4 aut |
700 | 1 | a Yeates, D.4 aut |
700 | 1 | a Freudenheim, J. L.4 aut |
700 | 1 | a Titus, L. J.4 aut |
700 | 1 | a Chang-Claude, J.4 aut |
700 | 1 | a Kaaks, R.4 aut |
700 | 1 | a Anderson, K. E.4 aut |
700 | 1 | a Lazovich, D.4 aut |
700 | 1 | a Robien, K.4 aut |
700 | 1 | a Hampton, J.4 aut |
700 | 1 | a Newcomb, P. A.4 aut |
700 | 1 | a Rossing, M. A.4 aut |
700 | 1 | a Thomas, D. B.4 aut |
700 | 1 | a Weiss, N. S.4 aut |
700 | 1 | a Lokkegaard, E.4 aut |
700 | 1 | a Riboli, E.4 aut |
700 | 1 | a Clavel-Chapelon, F.4 aut |
700 | 1 | a Cramer, D.4 aut |
700 | 1 | a Hankinson, S. E.4 aut |
700 | 1 | a Tamimi, R. M.4 aut |
700 | 1 | a Tworoger, S. S.4 aut |
700 | 1 | a Franceschi, S.4 aut |
700 | 1 | a La Vecchia, C.4 aut |
700 | 1 | a Negri, E.4 aut |
700 | 1 | a Adami, H. O.u Karolinska Institutet4 aut |
700 | 1 | a Magnusson, C.u Karolinska Institutet4 aut |
700 | 1 | a Riman, T.4 aut |
700 | 1 | a Weiderpass, E.u Karolinska Institutet4 aut |
700 | 1 | a Wolk, A.u Karolinska Institutet4 aut |
700 | 1 | a Schouten, L. J.4 aut |
700 | 1 | a van den Brandt, P. A.4 aut |
700 | 1 | a Chantarakul, N.4 aut |
700 | 1 | a Koetsawang, S.4 aut |
700 | 1 | a Rachawat, D.4 aut |
700 | 1 | a Palli, D.4 aut |
700 | 1 | a Black, A.4 aut |
700 | 1 | a Brinton, L. A.4 aut |
700 | 1 | a Freedman, D. M.4 aut |
700 | 1 | a Hartge, P.4 aut |
700 | 1 | a Hsing, A. W.4 aut |
700 | 1 | a Jnr, J. V. Lacey4 aut |
700 | 1 | a Lissowska, J.4 aut |
700 | 1 | a Hoover, R. N.4 aut |
700 | 1 | a Schairer, C.4 aut |
700 | 1 | a Babb, C.4 aut |
700 | 1 | a Urban, M.4 aut |
700 | 1 | a Graff-Iversen, S.4 aut |
700 | 1 | a Selmer, R.4 aut |
700 | 1 | a Bain, C. J.4 aut |
700 | 1 | a Green, A. C.4 aut |
700 | 1 | a Purdie, D. M.4 aut |
700 | 1 | a Siskind, V.4 aut |
700 | 1 | a Webb, P. M.4 aut |
700 | 1 | a Moysich, K.4 aut |
700 | 1 | a McCann, S. E.4 aut |
700 | 1 | a Hannaford, P.4 aut |
700 | 1 | a Kay, C.4 aut |
700 | 1 | a Binns, C. W.4 aut |
700 | 1 | a Lee, A. H.4 aut |
700 | 1 | a Zhang, M.4 aut |
700 | 1 | a Ness, R. B.4 aut |
700 | 1 | a Nasca, P.4 aut |
700 | 1 | a Coogan, P. F.4 aut |
700 | 1 | a Palmer, J. R.4 aut |
700 | 1 | a Rosenberg, L.4 aut |
700 | 1 | a Whittemore, A.4 aut |
700 | 1 | a Katsouyanni, K.4 aut |
700 | 1 | a Trichopoulou, A.4 aut |
700 | 1 | a Trichopoulos, D.4 aut |
700 | 1 | a Tzonou, A.4 aut |
700 | 1 | a Dabancens, A.4 aut |
700 | 1 | a Martinez, L.4 aut |
700 | 1 | a Molina, R.4 aut |
700 | 1 | a Salas, O.4 aut |
700 | 1 | a Lurie, G.4 aut |
700 | 1 | a Carney, M. E.4 aut |
700 | 1 | a Wilkens, L. R.4 aut |
700 | 1 | a Werner Hartman, Lindau Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)li3247we |
700 | 1 | a Manjer, Jonasu Lund University,Lunds universitet,Kirurgi,Forskargrupper vid Lunds universitet,Surgery,Lund University Research Groups4 aut0 (Swepub:lu)smi-jma |
700 | 1 | a Olsson, Håkanu Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-hol |
700 | 1 | a Kumle, M.4 aut |
700 | 1 | a Grisso, J. A.4 aut |
700 | 1 | a Morgan, M.4 aut |
700 | 1 | a Wheeler, J. E.4 aut |
700 | 1 | a Edwards, R. P.4 aut |
700 | 1 | a Kelley, J. L.4 aut |
700 | 1 | a Modugno, F.4 aut |
700 | 1 | a Onland-Moret, N. C.4 aut |
700 | 1 | a Peeters, P. H. M.4 aut |
700 | 1 | a Casagrande, J.4 aut |
700 | 1 | a Pike, M. C.4 aut |
700 | 1 | a Wu, A. H.4 aut |
700 | 1 | a Canfell, K.4 aut |
700 | 1 | a Miller, A. B.4 aut |
700 | 1 | a Gram, I. T.4 aut |
700 | 1 | a Lund, E.4 aut |
700 | 1 | a McGowan, L.4 aut |
700 | 1 | a Shu, X. O.4 aut |
700 | 1 | a Zheng, W.4 aut |
700 | 1 | a Farley, T. M. M.4 aut |
700 | 1 | a Holck, S.4 aut |
700 | 1 | a Meirik, O.4 aut |
700 | 1 | a Risch, H. A.4 aut |
710 | 2 | a Karolinska Institutetb Medicinsk onkologi4 org |
773 | 0 | t The Lancetg 385:9980, s. 1835-1842q 385:9980<1835-1842x 1474-547X |
856 | 4 | u https://portal.research.lu.se/files/1964498/8523694x primaryx freey FULLTEXT |
856 | 4 | u http://dx.doi.org/10.1016/S0140-6736(14)61687-1x freey FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/7432012 |
856 | 4 8 | u https://doi.org/10.1016/S0140-6736(14)61687-1 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:131237033 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy